{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:53:44Z","timestamp":1790538824546,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.blre.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T11:42:06Z","timestamp":1553341326000},"page":"68-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Recent landmark studies in follicular lymphoma"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-591X","authenticated-orcid":false,"given":"Marc","family":"Sorigue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.03.006_bb0005","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.blre.2019.03.006_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","article-title":"Pathogenesis of follicular lymphoma","volume":"31","author":"Lackraj","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.blre.2019.03.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0025","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hon.2378","article-title":"Refractoriness to immunochemotherapy in follicular lymphoma: predictive factors and outcome","volume":"35","author":"Sorigue","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0035","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0045","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0050","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0055","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0065","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00262","article-title":"Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic lymphoma group trials with more than 10 years of follow-up","author":"Lockmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0075","series-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression Haematologica","author":"Seymour","year":"2018"},{"key":"10.1016\/j.blre.2019.03.006_bb0080","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0085","first-page":"412","article-title":"Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials","volume":"130","author":"Casulo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0095","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0100","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the national LymphoCare study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0110","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2019.03.006_bb0115","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.blre.2019.03.006_bb0120","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.56.1","article-title":"Follicular lymphoma: the role of the tumor microenvironment in prognosis","volume":"56","author":"Sugimoto","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.blre.2019.03.006_bb0130","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the lymphoma study association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.blre.2019.03.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30339-5","article-title":"Predictive gene-expression score for follicular lymphoma \u2013 Authors' reply","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-017-3197-1","article-title":"Is there a role for the international prognostic index in follicular lymphoma?","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0145","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2019.03.006_bb0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0155","article-title":"Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016","author":"Qu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.3413","article-title":"DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control","volume":"47","author":"Kretzmer","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.blre.2019.03.006_bb0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.immuni.2014.12.021","article-title":"Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma","volume":"42","author":"Koues","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2019.03.006_bb0170","first-page":"441","article-title":"Prognostic significance of epigenetic inactivation of p16, p15","volume":"30","author":"Krajnovi\u0107","year":"2013","journal-title":"MGMT and DAPK genes in follicular lymphoma Med Oncol"},{"key":"10.1016\/j.blre.2019.03.006_bb0175","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0180","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/ejh.13093","article-title":"Treatment of localized-stage follicular lymphoma","volume":"101","author":"Sorigue","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0190","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0195","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","author":"Brady","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0200","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the national LymphoCare study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0205","first-page":"4148","article-title":"Outcomes of Stage I and II follicular lymphoma in the era of 18f-fdg pet-ct staging: an international collaborative study from the australian lymphoma alliance","volume":"132","author":"Joshua","year":"2018","journal-title":"ASH Meet"},{"key":"10.1016\/j.blre.2019.03.006_bb0210","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0215","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2018.79.3075","article-title":"Early-stage follicular lymphoma: what is the preferred treatment strategy?","volume":"36","author":"Yang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00259-018-4112-2","article-title":"Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone","volume":"46","author":"Ng","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.blre.2019.03.006_bb0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.03.006_bb0230","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0235","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucyl in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study","volume":"151","author":"Goede","year":"2018","journal-title":"EHA Meet."},{"key":"10.1016\/j.blre.2019.03.006_bb0240","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received Obinutuzumab plus Bendamustine induction and Obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0245","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with Obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0250","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0255","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2019.03.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.03.006_bb0265","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0270","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer research group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.03.006_bb0275","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low\u2013tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0280","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.2018.79.3083","article-title":"Progress in advanced-stage follicular lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0285","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/asheducation-2018.1.185","article-title":"Where to start? Upfront therapy for follicular lymphoma in 2018","volume":"2018","author":"Leonard","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.blre.2019.03.006_bb0290","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.15720","article-title":"Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma","volume":"184","author":"Hill","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0295","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjh.13863","article-title":"Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity","volume":"175","author":"Cheah","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0300","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.14667","article-title":"Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma","volume":"178","author":"Martin","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0305","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3026(18)30155-8","article-title":"Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial","volume":"5","author":"Watanabe","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2019.03.006_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0315","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","author":"Chiu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0325","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0330","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0335","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of Lenalidomide alone versus Lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0340","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0345","series-title":"AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab\/Placebo in Patients with Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma Blood","first-page":"132","author":"Leonard","year":"2018"},{"key":"10.1016\/j.blre.2019.03.006_bb0350","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.006_bb0355","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the lymphoma working party of the EBMT and the lymphoma committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.03.006_bb0360","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2019.03.006_bb0365","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.006_bb0370","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.006_bb0375","first-page":"1","article-title":"Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world","author":"Manna","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.blre.2019.03.006_bb0380","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-lymphoma working party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.006_bb0385","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.13947","article-title":"The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of \u226412 months","volume":"173","author":"Lunning","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00259-014-2896-2","article-title":"PET\/CT before autologous stem cell transplantation predicts outcome in refractory\/relapsed follicular lymphoma","volume":"42","author":"Alcantara","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.blre.2019.03.006_bb0395","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of Pretransplantation 18F-fluorodeoxy glucose\u2013positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2019.03.006_bb0400","article-title":"The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies","volume":"1","author":"Norman","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.blre.2019.03.006_bb0405","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for Allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.blre.2019.03.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0415","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.03.006_bb0420","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","author":"Link","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.03.006_bb0425","article-title":"Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era","volume":"2955","author":"Alperovich","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0430","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","author":"Rivas-Delgado","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0435","doi-asserted-by":"crossref","unstructured":"Cheson BD, O'Brien S, Ewer MS, Goncalves M, Farooki A, Lenz G, et al. Optimal Management of Adverse Events from Copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk 2018;0 (in press). doi:https:\/\/doi.org\/10.1016\/j.clml.2018.11.021.","DOI":"10.1016\/j.clml.2018.11.021"},{"key":"10.1016\/j.blre.2019.03.006_bb0440","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2019.03.006_bb0445","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0450","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.blre.2019.03.006_bb0455","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0460","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0465","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0470","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.blre.2019.03.006_bb0475","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0480","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0485","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/blood-2018-99-114620","article-title":"A novel prognostic model that is superior to FLIPI-1 and FLIPI-2 and integrates clinical and treatment factors to predict progression-free survival and early treatment failure in patients with follicular lymphoma in the GALLIUM trial","volume":"130","author":"Mir","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0490","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/0284186X.2017.1349927","article-title":"Debate on the value of end-of-treatment FDG-PET response evaluation in follicular lymphoma","volume":"56","author":"Adams","year":"2017","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.blre.2019.03.006_bb0495","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.blre.2019.03.006_bb0500","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2018-99-117235","article-title":"Baseline PET-derived metabolic tumor volume metrics did not predict outcomes in follicular lymphoma patients treated with first-line Immunochemotherapy and antibody maintenance in the phase III GALLIUM study","volume":"130","author":"Barrington","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.03.006_bb0505","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.15513","article-title":"Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study","volume":"183","author":"Gyan","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2019.03.006_bb0510","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18301401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:34Z","timestamp":1759436554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18301401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":102,"alternative-id":["S0268960X18301401"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.006","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent landmark studies in follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}